论文部分内容阅读
最新公布的III期临床数据显示,telaprevir——首个治疗丙肝的蛋白酶抑制剂,显著提高了丙肝的治愈率,给丙肝药物研发带来了美好的前景。
The newly released phase III clinical data show that telaprevir, the first protease inhibitor to treat hepatitis C, significantly improves the cure rate of hepatitis C, bringing promising future for hepatitis C drug development.